31 related articles for article (PubMed ID: 3409241)
1. The Crystal Structure of Oxaliplatin: A Case of Overlooked Pseudo Symmetry.
Johnstone TC
Polyhedron; 2014 Jan; 67():. PubMed ID: 24415827
[TBL] [Abstract][Full Text] [Related]
2. Biotransformation research advances - 2022 year in review.
Khojasteh SC; Argikar UA; Cheruzel L; Cho S; Crouch RD; Dhaware D; Heck CJS; Johnson KM; Kalgutkar AS; King L; Liu J; Ma B; Maw H; Miller GP; Seneviratne HK; Takahashi RH; Wang S; Wei C; Jackson KD
Drug Metab Rev; 2023 Nov; 55(4):301-342. PubMed ID: 37737116
[TBL] [Abstract][Full Text] [Related]
3. Biological relevance of interaction of platinum drugs with
Gorle AK; Berners-Price SJ; Farrell NP
Inorganica Chim Acta; 2019 Sep; 495():. PubMed ID: 31354168
[TBL] [Abstract][Full Text] [Related]
4. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
Wang S; Zhang H; Scharadin TM; Zimmermann M; Hu B; Pan AW; Vinall R; Lin TY; Cimino G; Chain P; Vuyisich M; Gleasner C; Mcmurry K; Malfatti M; Turteltaub K; de Vere White R; Pan CX; Henderson PT
PLoS One; 2016; 11(1):e0146256. PubMed ID: 26799320
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin and its enantiomer induce different condensation dynamics of single DNA molecules.
Zhang HY; Liu YR; Ji C; Li W; Dou SX; Xie P; Wang WC; Zhang LY; Wang PY
PLoS One; 2013; 8(8):e71556. PubMed ID: 23951187
[TBL] [Abstract][Full Text] [Related]
6. Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells.
King CL; Ramachandran S; Chaney SG; Collins L; Swenberg JA; DeKrafft KE; Lin W; Cicurel L; Barbier M
Cancer Chemother Pharmacol; 2012 Mar; 69(3):665-77. PubMed ID: 21968950
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
Lévi F; Metzger G; Massari C; Milano G
Clin Pharmacokinet; 2000 Jan; 38(1):1-21. PubMed ID: 10668856
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin.
Screnci D; Er HM; Hambley TW; Galettis P; Brouwer W; McKeage MJ
Br J Cancer; 1997; 76(4):502-10. PubMed ID: 9275028
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.
Petros WP; Chaney SG; Smith DC; Fangmeier J; Sakata M; Brown TD; Trump DL
Cancer Chemother Pharmacol; 1994; 33(4):347-54. PubMed ID: 8281629
[TBL] [Abstract][Full Text] [Related]
11. Chemical stability, biological activity and cellular uptake of a cisplatin analogue having a 1,2-diarylethyleneamine ligand in cultures of human breast cancer cells.
Otto AM; Kratochwil NA; Eggers H; Bednarski PJ
J Cancer Res Clin Oncol; 1995; 121(1):31-8. PubMed ID: 7860616
[TBL] [Abstract][Full Text] [Related]
12. New cisplatin analogues in development. A review.
Weiss RB; Christian MC
Drugs; 1993 Sep; 46(3):360-377. PubMed ID: 7693428
[TBL] [Abstract][Full Text] [Related]
13. Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.
Thompson DC; Vaisman A; Sakata MK; Wyrick SD; Holbrook DJ; Chaney SG
Cancer Chemother Pharmacol; 1995; 36(5):439-47. PubMed ID: 7634386
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of tetrachloro(d,l-trans)1,2-diaminocyclohexane-platinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses.
Carfagna PF; Poma A; Wyrick SD; Holbrook DJ; Chaney SG
Cancer Chemother Pharmacol; 1991; 27(5):335-41. PubMed ID: 1998992
[TBL] [Abstract][Full Text] [Related]
15. Synergistic cytotoxic actions of cisplatin and liposomal valinomycin on human ovarian carcinoma cells.
Daoud SS; Forde NH
Cancer Chemother Pharmacol; 1991; 28(5):370-6. PubMed ID: 1914081
[TBL] [Abstract][Full Text] [Related]
16. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.
Mauldin SK; Gibbons G; Wyrick SD; Chaney SG
Cancer Res; 1988 Sep; 48(18):5136-44. PubMed ID: 3409241
[TBL] [Abstract][Full Text] [Related]
17. Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line.
Mauldin SK; Husain I; Sancar A; Chaney SG
Cancer Res; 1986 Jun; 46(6):2876-82. PubMed ID: 3698013
[TBL] [Abstract][Full Text] [Related]
18. An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.
Chaney SG; Gibbons GR; Wyrick SD; Podhasky P
Cancer Res; 1991 Feb; 51(3):969-73. PubMed ID: 1988140
[TBL] [Abstract][Full Text] [Related]
19. In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma.
Chaney SG; Wyrick S; Till GK
Cancer Res; 1990 Aug; 50(15):4539-45. PubMed ID: 2196115
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
